EP3380109A1 - Composition pour le traitement de refroidissements et d'allergies - Google Patents

Composition pour le traitement de refroidissements et d'allergies

Info

Publication number
EP3380109A1
EP3380109A1 EP16751231.8A EP16751231A EP3380109A1 EP 3380109 A1 EP3380109 A1 EP 3380109A1 EP 16751231 A EP16751231 A EP 16751231A EP 3380109 A1 EP3380109 A1 EP 3380109A1
Authority
EP
European Patent Office
Prior art keywords
range
composition
weight
component
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16751231.8A
Other languages
German (de)
English (en)
Inventor
Anna-Maria Vestweber
Markus UNKAUF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maria Clementine Martin Klosterfrau Vertriebs GmbH
Original Assignee
Maria Clementine Martin Klosterfrau Vertriebs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maria Clementine Martin Klosterfrau Vertriebs GmbH filed Critical Maria Clementine Martin Klosterfrau Vertriebs GmbH
Publication of EP3380109A1 publication Critical patent/EP3380109A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/723—Xanthans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/09—Lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8988—Gastrodia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • composition for the treatment of colds and allergies Composition for the treatment of colds and allergies
  • the present invention relates to the field of treatment of respiratory diseases, in particular colds and / or allergies.
  • the present invention relates to a composition which is suitable for the prophylactic or therapeutic treatment of respiratory diseases, in particular of common colds or of allergies. Moreover, the present invention relates to the use of this composition according to the invention.
  • respiratory tract synonymously also referred to as respiratory tract or respiratory apparatus
  • the airways are divided into the upper sections, which include the nasal cavity with its sinuses and the throat, and the lower airways, which are the larynx, the trachea, and the entire branch of the bronchial tree, i. H. also include the lungs, divided.
  • the respiratory tract can be affected by diseases of various causes. Most commonly, respiratory diseases are based on inflammatory, infectious or allergic processes or even combinations of several of the aforementioned causes. Commonly occurring respiratory diseases include in particular respiratory infections, such as influenza infections or colds, bronchitis and pneumonia, respiratory allergic diseases, especially allergic cold or asthma, and chronic obstructive airway diseases.
  • Respiratory diseases often show similar symptoms, regardless of the underlying cause.
  • symptoms such as runny nose, coughing, irritation of the mucous membranes and swollen mucous membranes on the pharynx, in the nose and on the eyes, hoarseness and impaired breathing are associated with the abovementioned disorders.
  • fever, headache and general malaise may also accompany the symptoms.
  • respiratory diseases in the western population are one of the most common causes of doctor visits or sick leave, the previously known therapeutic approaches for alleviating the symptoms associated with respiratory diseases are often unsatisfactory, as explained in detail below.
  • both of infectious colds and allergic rhinitis usually decongestant nasal sprays based on vasoconstrictors, in particular alpha-sympathomimetics, are used, which, however, are often associated with serious side effects.
  • the nasal mucosa dries out and it can come to certain habituation effects to dependency.
  • the vasoconstrictor effect can lead to serious systemic side effects, such as reduced blood flow.
  • the herbal nasal sprays known in the prior art are better tolerated, but have no good activity.
  • the medicaments or compositions customarily used for the treatment of, in particular, allergic respiratory diseases are also not optimal, in particular with regard to their side-effect profile.
  • corticosteroid-based drugs can lead to side effects such as obesity, increased blood pressure and edema or water retention.
  • the antihistamines used in particular in the treatment of allergic rhinitis can also lead to unpleasant side effects, such as severe fatigue.
  • the present invention is therefore based on the object to provide a composition which is suitable for the treatment of respiratory diseases, especially colds and / or allergies, and which are the disadvantages of the prior art described above at least largely avoids or at least mitigates.
  • composition which, in the context of the treatment of respiratory diseases, in particular colds and / or allergies, has an improved efficacy, in particular with regard to the alleviation of inflammation, pain, irritated mucous membranes and allergic-related complaints, and, moreover, an improved side-effect profile having.
  • the present invention proposes - according to the first aspect of the present invention - a composition according to claim 1; Further, particularly advantageous embodiments of the composition according to the invention are the subject of the relevant subclaims.
  • the present invention is based on the use according to the invention of compositions according to the present invention, as defined in the use claimed therefor.
  • the present invention is a composition, in particular a pharmaceutical composition, which is preferably suitable for use in the prophylactic and / or therapeutic treatment of respiratory diseases, in particular colds and / or allergies.
  • composition in combination and in each case in effective, in particular pharmaceutically effective amounts
  • component (a) at least one homeopathic active substance which is active against colds and / or allergies ("component (a)");
  • compositions for the treatment of by most diverse Causes triggered respiratory diseases, especially colds or allergies, provided can be compared to the prior art have an improved profile of action and, moreover, fewer side effects.
  • the present invention is associated with numerous advantages and particularities, which are discussed below in a non-limiting manner and are to be regarded as an indication of patentability.
  • composition according to the invention On the basis of the composition according to the invention an effective agent for the treatment of respiratory diseases, especially colds and / or allergies, provided, which is free of drugs with strong side effects, such as vasoconstrictors, antihistamines, cortisone or anti-inflammatories, eg. Aspirin or paracetamol.
  • the composition according to the invention thus harbors at least essentially no risk of, in particular, systemic side effects or incompatibilities frequently associated with the abovementioned active ingredients or active ingredient classes.
  • the homeopathic active substances used in the context of the present invention show - especially in the context of the combination according to the invention with at least one mucilaginous or at least one mucilage - an excellent efficacy in relation to the symptoms of respiratory diseases, such as (allergic or cold-induced) runny nose, cough, Hoarseness and / or general allergic complaints.
  • respiratory diseases such as (allergic or cold-induced) runny nose, cough, Hoarseness and / or general allergic complaints.
  • inflammation states can also be effectively treated with the abovementioned active ingredient combination according to the invention.
  • the active ingredients used according to the invention ie the at least one homeopathically effective active ingredient on the one hand and the at least one mucous drug or the at least one mucilage on the other hand complement each other in a synergistic manner.
  • the mucus drug or mucilages form a film-like, dense matrix on the mucous membrane, ie a protective protective layer is built up.
  • the irritated and dry mucous membrane of the respiratory tract is rehydrated and regenerated on this basis so that the homeopathic active ingredients can develop their effect there with greater efficiency.
  • the used homeopathic active ingredient is further enhanced by the mucosal protection in its specific effect, so that the effect of the respective individual active ingredients in combined use on the effect when administered alone significantly.
  • the compositions according to the invention have excellent wound healing properties.
  • the combination of active substances according to the invention leads to a rapid regeneration and a swelling of the irritated mucous membrane.
  • the regenerating or regenerated mucosa is also protected on the basis of the formation of the protective film described above, in particular against the penetration of other pathogens, since the protective film has a certain barrier effect against these.
  • the compositions according to the invention also lead to an excellent alleviation of the respiratory symptoms accompanying pain symptoms.
  • the associated with irritated mucosa pain in coughing, runny nose or hoarseness can be alleviated with the compositions of the invention.
  • compositions according to the invention are extremely convenient to use and can be tailored to the dosage form, depending on the intended use.
  • the compositions according to the invention may be lozenges or lozenges, solutions or juices or aerosols or sprays which are preferably to be administered nasally.
  • the active profile and stability behavior of the composition according to the invention can be further controlled or specifically adjusted.
  • compositions of the invention are also very variable in use and are suitable for the treatment of a variety of respiratory diseases. Both the typical symptoms associated with influenza infections and colds, such as sore throat, hoarseness, runny nose and cough, as well as the symptoms associated with allergies, especially allergic rhinitis, irritation of the mucous membranes and burning or watery eyes, can be at high efficacy at the same time low Treat side effects with the compositions of the invention successfully.
  • pharmaceutical composition or “pharmaceutical preparation”, as used in the context of the present invention, is to be understood broadly and includes not only pharmaceutical preparations or pharmaceuticals and pharmaceuticals as such, but in particular also homeopathic remedies, so-called medical devices, foods or dietary supplements.
  • respiratory diseases are understood to be, in particular, diseases affecting the respiratory tract or the respiratory tract.
  • the respiratory tract comprises an upper portion including the nasal cavity, pharynx, and paranasal sinuses, and a lower portion comprising the larynx, trachea, and branch of the bronchial tree, including the lungs.
  • the respiratory tract diseases to be treated with the composition according to the invention may be infectious, d. H. act by infections with pathogens, especially bacteria, viruses or fungi, triggered respiratory diseases. These are preferably colds or flu infections, bronchitis, cough, runny nose and / or sinusitis.
  • respiratory diseases in the context of the present invention also means allergic respiratory diseases or respiratory diseases caused by allergies and / or by contact with allergens, in particular allergic rhinitis or allergic rhinitis. Allergic rhinitis can be triggered in particular by various pollen, house dust and / or fungi as allergens.
  • the term homeopathic active ingredient is understood as meaning active ingredients which are obtained by means of recognized homeopathic preparation methods. These are, in particular, the mother tinctures obtained from vegetable basic substances.
  • the term “mother tinctures” refers to the concentrated, liquid preparation of a vegetable compressed juice preferably mixed with ethanol or a plant extract and / or plant extract.
  • the homeopathic active ingredient may also be present as a diluted, in particular potentiated, solution based on the respective mother tincture.
  • these are in particular drugs derived from fungi, plants, animals or microorganisms, which are water-binding biopolymers, in particular polysaccharides, as ingredients.
  • the biopolymers or polysaccharides are usually heteropolysaccharides with molecular weights of about 50,000 to 2,000,000, which are obtained by extraction with hot or cold water from the drug.
  • the high-viscosity solutions are not tacky in contrast to the gums.
  • a distinction can be made between acidic and neutral slime.
  • the mucus of the marshmallow root can be regarded as a prototype for an acid mucus. It contains L-rhamnose, D-galactose, D-galacturonic acid and D-glucuronic acid in a molecular ratio of approximately 3: 2: 3: 3.
  • the simplest built part of the polysaccharide consists of repeating undecasaccharide subunits.
  • mucilages are understood in particular to mean macromolecular carbohydrates whose molecules consist of a number of at least> 10 glycosidically linked monosaccharide molecules.
  • the mucilage includes numerous biopolymers or polymers of biogenic origin, which can have extremely variable chemical or pharmacological properties.
  • Polysaccharides are mainly used as reserve substances and are usually present as homopolymers or homoglycans, which are each based on one type of monosaccharide.
  • there are mucilages which can bind large amounts of water under gelation.
  • the use of mucilage has proven to be particularly advantageous because they show a particularly strong affinity for the oral, nasal or pharyngeal mucosa and form a protective film, so to speak, which protects the mucous membrane against the entry of pathogens such as cold viruses , and on the other hand prevents fluid loss or the symptoms of dry mouth.
  • the active ingredients or active components used in the compositions according to the invention complement each other synergistically. Due to the mucous drugs or mucilages used, a kind of protective matrix is formed on the irritated and damaged mucous membrane, which in particular also prevents further drying out.
  • the homeopathic agents used can reach the site of action with greater efficiency of action and unfold their effect there. On this basis, both a rapid onset of action as well as an excellent efficiency and a long-lasting duration of action are guaranteed.
  • the present invention may be configured in a variety of ways. Preferred embodiments are described in detail below.
  • the homeopathic active ingredient and / or component (a) is at least one ingredient isolated and / or extracted from plants.
  • the plants are selected from the group of Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, Arum triphyllum and / or Galphimia glauca.
  • the homeopathic active ingredient and / or the component (a) is at least one plant-derived extract or its component.
  • the plants may be selected in particular from the group of Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, Arum triphyllum and / or Galphimia glauca.
  • the plants of the genus Drosera are different species or species of the sundew.
  • Drosera rotundifolia, Drosera intermedia and / or Drosera anglica have proven to be particularly effective for the use according to the invention.
  • the sundew is known as a carnivorous plant and occurs mainly in Asian and North American, but partly also in European peat bogs.
  • the homeopathic active ingredients of sundew are produced in particular from the flowers of the plants.
  • the extraction of the active ingredients or the preparation of the mother tincture can in particular according to instructions 1 .1 .3 of the Code of Practice 2371 of the Ph. Eur. (See also V 2a Homeopathic Pharmacopoeia (HAB)) with ethanol.
  • HAB Homeopathic Pharmacopoeia
  • homeopathic active substances from Drosera rotundifolia, Drosera intermedia and / or Drosera anglica have outstanding efficacy in the treatment of symptoms of respiratory diseases. especially pain, hoarseness and coughing.
  • the homeopathic agents are characterized by their excellent anti-inflammatory effect in the context of the treatment of respiratory diseases, which can be completely further enhanced by the additional use of mucus drugs or mucus substances even further.
  • the plant Arum triphyllum synonymous also Arisaema triphyllum or three-leaved Aaronstab or Zehrwurzel, is a poisonous plant, which is native to America and China.
  • Aaronstab contains large quantities of oxalate, fugitive pungent substances, the bitter saponin Aroin and the alkaloid Coniin, which can cause severe poisoning even in small amounts when in contact with or ingestion of plant parts. Only by boiling or drying the Aaronstab loses its toxicity.
  • the extraction of the active ingredients or the preparation of the mother tincture can in particular according to regulation 1 .1 .5 of the set of regulations 2371 of Ph.Eur. (V 3a HAB) with ethanol.
  • To provide the mother tincture in particular the tuber or root of the plant can be used.
  • the homeopathic active substances from Arum triphyllum in particular in combination with the other active components used according to the invention, have outstanding properties with regard to alleviating inflammatory symptoms on the respiratory tract, in particular the upper respiratory tract.
  • the active ingredients from the zehoot root also lead to a significant alleviation of pain associated with respiratory diseases pain.
  • Galphimia glauca is also a poisonous plant, which is synonymously or in German also referred to as small laburnum and as a shrub growing mainly in Central America and Mexico.
  • the mother tincture can be prepared in particular according to the Homeopathic Pharmacopoeia (HAB 2000).
  • homeopathic active substances based on Galphimia glauca have an outstanding effectiveness, in particular in the treatment of allergic complaints, sneezing, stuffy nose and intense itching on the palate, in the throat or throat and on the nasal mucosa.
  • a dryness of the mucous membranes can be significantly alleviated.
  • the aforementioned homeopathic active ingredients can be obtained or provided in particular by the provision of so-called mother tinctures.
  • mother tinctures are in particular concentrated, liquid preparations which are obtained by pressing out plant components and then mixing the resulting compressed juice with solvents, in particular ethanol, or by extracting or extracting the plant components with suitable extraction agents, such as ethanol ,
  • solvents in particular ethanol
  • suitable extraction agents such as ethanol
  • both fresh and dried components of the aforementioned plants can be used.
  • the plant components may be subjected to maceration, heat treatment, decoction or fermentation before being pressed out or before extraction.
  • the provided mother tinctures can be further mixed or diluted, which is also called potentizing.
  • the component (a) and / or the homeopathic active ingredient by aqueous, aqueous-alcoholic or alcoholic extraction of plant components, especially the plants Drosera, especially Drosera rotundifolia, Dosera intermedia and / or Drosera anglica, Arum triphyllum and / or Galvinia glauca, to obtain a mother tincture.
  • the mother tinctures are used in dilute form in accordance with customary homeopathic practice, the dilution taking place in particular by means of potentiation.
  • the previously obtained mother tincture is gradually shaken with water and / or alcohol to provide it with respect to the mother tincture of low-concentrated solutions of the homeopathic active ingredients, or alternatively triturated with milk sugar.
  • mother tincture which initially in the ratio of 1: 10, ie one part mother tincture and 9 parts solvent, 1: 100 (one part mother tincture, 99 parts solvent) or 1: 50,000 (one part mother tincture, 49.999 parts solvent) diluted with a solvent and then shaken with a fixed number of strokes. The combination of dilution and shaking is carried out in each potentiating step.
  • centimal potencies C potencies, dilution 1: 100 per step and 10 shakes
  • D potencies quinquaginta in decimal potencies
  • Q potencies, dilution 1: 50,000 with 100 shakes and use of an additional carrier substance are assumed.
  • the effectiveness of the at least one homeopathic active ingredient in the compositions according to the invention it has proven to be particularly advantageous to dilute the mother tinctures in D-potencies, ie in dilution steps of 1:10.
  • the homeopathic active ingredient and / or component (a) have a decimal potency in the range from D1 to D30, in particular in the range from D2 to D15, preferably in the range from D3 to D10, is preferably used in the range of D4 to D7, based on the mother tincture of the homeopathic active ingredient.
  • the composition according to the invention comprises the homeopathic active ingredient and / or component (a) in an amount in the range from 0.00001 to 10% by weight. %, in particular in the range of 0.0001 to 5 wt.%, preferably in the range of 0.0005 to 4 wt.%, preferably in the range of 0.0009 to 3 wt.%, relative to the composition, contains.
  • component (b) it is also provided in the context of the present invention that it is selected from at least one mucilage and / or at least one mucus drug.
  • the grain Component (b) be formed either by at least one mucilaginous drug, by at least one mucilage or by a combination of mucous drug (s) and mucilage (s).
  • mucous drugs particularly good results are obtained if the at least one mucilaginous drug is selected from the group of Iceland moss (Liehen islandicus), marshmallow (Althaea officinalis L.), plantain (Plantago lanceolata L.), mallow ( Malva sylvestris L. and M.
  • the at least one mucilaginous drug may in particular be selected from the group of Icelandic moss (Liehen islandicus), marshmallow (Althaea officinalis L.) and / or mallow (Malva sylvestris L. and M. neglecta WALLR.) And combinations thereof ,
  • Icelandic moss is the German name for Liehen islandicus or Cetraria islandica (Parmeliaceae), ie a lichen (which is not a moss contrary to the German name), which is exported from northern countries such as Iceland, Norway and Sweden.
  • Icelandic moss in the true sense consists in particular of the dried thallus of Cetraria islandica and its preparations.
  • the drug contains, among other things, mucilage and bitter substances as well as bitter tasting lichen acids. About 60 wt .-% dissolve from the powdered lichen on boiling with highly dilute sodium bicarbonate solution, and upon cooling of the solution, a jelly.
  • the extract consists of a polysaccharide mixture of lichenin and isolichenin, a series of bitter-tasting lichen acids (fumarprotocetrar, protocetraric and cetraric acid) and protolichesteric acid, which converts to lichesteric acid during work-up, and usnic acid as an antibiotic lichen dye.
  • Icelandic moss has soothing properties, it also has an antimicrobial effect. The Bitterstoffgehalt justified its use in loss of appetite. Icelandic moss is used for example in catarrh and diarrhea, as bitter tonic, externally in poorly healing wounds, in cosmetic preparations, in loss of appetite and in irritation of the mucous membranes in the mouth and throat.
  • An oral and Rachendesinfiziens based on Icelandic moss has a soothing effect on dry irritated cough.
  • the cold macerate and other bitter-tasting preparations of the drug are used to remedy the sub- or antacidity.
  • the dosage forms used include the comminuted drug for infusions and other galenical preparations or the crushed drug is preferably used for cold macerates as well as other bitter-tasting preparations for oral use.
  • the marshmallow (Althaea officinalis L.), especially used in the form of the marshmallow root, leaves and flowers, grows on saline and moist soils of Central, Eastern and Southeastern Europe.
  • the brown color of the peeled drug means a reduction in quality; a subsequent "beauty" with sulfite solution is inadmissible.
  • Also used are the approximately 10 cm long, about 8 cm wide, three- to five-lobed, gray-haired, hairy dried leaves collected before or during flowering and the flesh-colored dried petals collected in July / August.
  • the marshmallow is a perennial, about 1 m high perennial that is generative or vegetatively propagated.
  • the root harvested in late autumn contains up to 15% mucilage.
  • the mucus content is 5 to 6%.
  • the mucus content of the leaf and flower drug is 6 to 9%.
  • the mucus is localized in the root in certain mucous cells of the bark and wood parenchyma. It consists of galacturonorhamnanes, glucans and arabinogalactans.
  • Aqueous extracts from the root should be prepared by maceration at room temperature so that the abundant starch does not interfere with swelling.
  • Marshmallow drugs are used for tea preparations or for making Sirupus Althaeae.
  • the main application area is inflammatory irritation of the pharynx. Externally, the marshmallow is used for softening envelopes, baths and cataplasms.
  • the plantain ⁇ Plantago lanceolata L.) is distributed throughout Europe as well as in North and Central Asia. The drug comes from wild plants and cul- especially in southeastern Europe. The dried, olive to brownish green colored, lanceolate leaf blades with about three to seven parallel nerves can be used.
  • the herba drug consists of the dried leaves, stems and whole flowers.
  • the Spitzwege- rieh further contains tannins, the iridoid glycoside aucubin (1, 9 to 2.4%), which is responsible for the dark coloration of a drug that has not been carefully dried and is used for identity verification, and also the mustard oil sulforaphane.
  • the ribwort plantain, in particular the plantain leaf herb finds particular application in the form of teas and syrups in inflammation of the mouth and throat.
  • the mallow (Malva sylvestris L. and M. neglecta WALLR.), Especially in the form of mallow flowers and leaves, is native to Europe, Asia Minor, the Mediterranean and the Near East.
  • the mallow is a herb of two to several years.
  • the mucus content of flowers and leaves is 6 to 8%. In the hydrolysis, the mucus gives glucose, arabinose, rhamnose and galactose. Mallow flowers are used as gargle waters and barks and along with the leaves in tea blends as expectorans.
  • the fenugreek (Trigonella foenum-graecum L.), especially used in the form of the fenugreek seed, is found throughout the Mediterranean, as well as in Eastern Europe, India and China.
  • the main drug import comes from the cultures of India and Morocco. Used are the brown-reddish, four-sided and diamond-shaped, about 5 mm long and about 3 mm wide, flattened, very hard seeds that are characterized by a furrow.
  • the drug contains 20-30% mucus, trigonellin, nicotinic acid amide, choline, bitter substances and saponins in addition to fatty oil.
  • the production of the mucus takes place from the powdered seed.
  • the powder is used externally to envelopes in boils, ulcers and glandular swelling, internally as an expectorant and Roborans.
  • Salep or Salep Tuber especially used in the form of the Salep tuber, is derived from various species of orchids, especially Orchis mascula L., Orchis morio L., Orchis militaris L., Anacamptis pyramidalis L. RICH. and Piatanthera bifolia L. RICH.
  • Salepschleim which consists up to 50% predominantly of glucomannan or glucan, is mainly used in children's nursing practice as antidiarrhoeal.
  • the quince (Cydonia oblonga MILL.) Is native to southeastern Arabia. Skin drug imports come from Spain, Portugal and Persia. The mature, dried, red-brown to brown-purple colored, slightly flattened seeds of the quince fruit are used. The seeds are on the outside partially provided with a dried-up mucus crust and often glued together. They have a weak bitter almond taste. In the epidermis is found about 22% mucus, which is largely soluble in water. The sugar components are arabinose, xylose and uronic acid, which is partially methylated. The drug is used only uncrushed. The quince mucus is used externally in lip and nipple humors, in burns and bedsores in ointment or cream form.
  • the mucous drug may preferably be Marshmallow (Althaea officinalis L.) and / or Icelandic Moos ⁇ Liehen islandicus) and / or Mallow (Malva sylvestris L. and M. neglecta WALLR.).
  • the at least one slime drug is used in the form of an extract, in particular a liquid extract and / or fluid extract.
  • the at least one mucilaginous drug is used in the form of an aqueous, alcoholic or aqueous-alcoholic extract, in particular an alcoholic or aqueous-alcoholic extract.
  • the effectiveness of the composition according to the invention can be further increased even further, if the at least one mucilaginous drug in the form of an extract, in particular liquid extract, with a drug / extract ratio of at least 0.5: 1, in particular at least 0.6: 1, preferably at least 0.8: 1, more preferably at least 0.9: 1 or more is used.
  • the so-called drug / extract ratio (DEV) characterizes the (weight-related) ratio of starting drug used to extract obtained.
  • the drug / extract ratio thus indicates from which weight-related amount of drug used (eg Liehen islandicus) which weight-related amount of extract has been obtained.
  • a drug / extract ratio for example, of 10: 1 means that one part by weight of extract was obtained from ten parts by weight of the drug.
  • the drug / extract ratio thus indicates how many parts by weight of a drug drug are required for the preparation of the weight-related extract equivalent.
  • the use of extracts with defined drug / extract ratio is particularly relevant in the light of the fact that the quality of the extract has a decisive influence on the overall quality of the pharmaceutical composition.
  • the aim is also to standardize the extract in terms of drug concentration, so that the final pharmaceutical preparation can be provided qualitatively and quantitatively with consistently good levels of active ingredients and ingredients.
  • the at least one mucilage is selected from the group of carrageenans and / or their physiologically tolerated salts, hyaluronic acid and / or their physiologically acceptable salts (eg alkali hyururonates) and / or Xanthanes and / or their physiologically acceptable salts.
  • hyaluronic acid or its salts, in particular sodium hyaluronate, used according to the invention are acidic glycosaminoglycans in the form of linear mucopolysaccharides, which are formed from repeating saccharides.
  • hyaluronic acid is a macromolecular chain of disaccharides based on D-glucuronic acid and N-acetyl-D-glucosamine, which are linked by a beta-1,3-glycosidic linkage.
  • the disaccharides are linked together via a ⁇ -1,4-glycosidic bond to form a polymeric chain.
  • a hyaluronic acid polymer consists of 250 to 50,000 disaccharide units.
  • Hyaluronic acid is an important component of connective tissue in the human or animal body and also plays a role in cell proliferation and cell migration. In the context of the present invention, in particular the cell proliferative effect with respect to a rapid regeneration of the tissue has proved to be advantageous.
  • hyaluronic acid has the ability to bind extremely large amounts of water: Thus, with 1 g of hyaluronic acid up to 6 liters of water can be bound. By binding large amounts of water, dehydration of the skin or mucous membrane can be prevented in an efficient manner, so that accelerated regeneration of the tissue is made possible and the skin or mucous membrane also remains elastic.
  • carrageenan or “carrageenan” is understood to mean a collective name for a group of long-chain polysaccharides which occur or are synthesized in particular in cells of different types of red algae.
  • Carrageenans are linear anionic hydrocolloids, with different types of carriers depending on the chemical structure. Due to the particular structure, different properties also result for the different types. The assignment is based primarily on the proportion of galactose and 3,6-anhydrogalactose and the number of sulfate groups. To produce carrageenan from red algae these are first washed and boiled in alkaline solution. Subsequently, the solution is filtered to separate the cell debris from the polymer.
  • the carrageenan is finally either precipitated by means of alcohol or gelled by means of potassium chloride and then pressed off.
  • the carrageenan recovered can then be dried, ground and further processed depending on the intended use.
  • kappa, iota and lambda carrageenan Of particular commercial interest are, in particular, kappa, iota and lambda carrageenan. Nevertheless, other types of carrageenan can alternatively be used, which then serve in particular as precursors for kappa, iota and lambda carrageenan.
  • the at least one mucilage is selected from the group of carrageenans, in particular alpha, iota, gamma, kappa and / or lambda carrageenan and / or physiologically acceptable salts
  • carrageenans in particular alpha, iota, gamma, kappa and / or lambda carrageenan and / or physiologically acceptable salts
  • xanthan in the context of the present invention, a natural polysaccharide understood, which contains as monomers, in particular glucose, glucuronic acid, mannose and, moreover, pyruvic acid.
  • the backbone of the xanthan polymer is formed in particular by beta-1,4-linked D-glucose units.
  • every second glucose unit via alpha-1, 3-glycosidic bonds is a beta-D-mannopyranosyl- (1,4) -beta-D-glucuronapyranosyl- (1,2) -6-0-acetyl-alpha-D -manno pyranosyl side chain knotted.
  • about half of the terminal mannose units of the side chain form a ketal with pyruvic acid via the free hydroxyl groups at positions 4 and 6.
  • the acetyl group or a side chain is completely absent.
  • xanthan gum is obtained with the aid of microorganisms of the genus Xanthomonas, starting from sugary substrates, and used industrially as thickening or gelling agent.
  • xanthan has water-binding properties and swells in aqueous solution, so that the viscosity of the medium is increased.
  • xanthan gum also prevents the mucous membranes from drying out or leads to a relief of dried out mucous membrane.
  • Xanthan gum also enhances the formation of a protective film on the mucosa.
  • the amount of mucous or mucilage or component (b) used can vary within wide limits. Particularly good results are achieved if the composition according to the invention comprises the at least one mucous drug and / or the at least one mucilage and / or component (b) in an amount in the range of 0.00001 to 30 wt .-%, in particular in the range of 0 , 0001 to 20 wt .-%, preferably in the range of 0.005 to 15 wt .-%, preferably in the range of 0.001 to 10 wt .-%, based on the composition.
  • the abovementioned mucilages and / or mucous drugs can each be used individually or in combinations.
  • the composition comprises at least one further active substance and / or ingredient, in particular selected from the group of (mucous) skin protection agents, anti-skinning septicemia, local anesthetics, vitamins, trace elements, minerals, micronutrients and their combinations.
  • the composition contains at least one customary pharmaceutical additive and / or adjuvant, in particular selected from the group of processing aids, stabilizers, emulsifiers, antioxidants, preservatives, humectants, pH adjusters, pH buffering agents, thickeners , Flavorings, Antiseptics, Coloring, Buffering, Perfuming, Fragrance, Stretching, Binding, Wetting and / or Preservatives and their combinations.
  • processing aids stabilizers, emulsifiers, antioxidants, preservatives, humectants, pH adjusters, pH buffering agents, thickeners , Flavorings, Antiseptics, Coloring, Buffering, Perfuming, Fragrance, Stretching, Binding, Wetting and / or Preservatives and their combinations.
  • the composition is present as a solid dosage form or that the composition is present as a tablet, dragee, pill, hard caramel or the like.
  • the composition according to this preferred embodiment is present as a lozenge.
  • the solid dosage form, in particular the lozenge has a total weight in the range from 0.5 to 7 g, in particular in the range from 1 to 6 g, preferably in the range from 2 to 5 g.
  • the solid dosage form is formed such that the solid dosage form releases a therapeutically effective amount of the active ingredients and / or ingredients in sucking when the solid dosage form is in the mouth and throat of a patient is administered and sucked.
  • composition according to the invention is concerned in the form of a solid dosage form, it has proved to be advantageous in this context if it contains the active ingredients and / or ingredients in a solid matrix and / or mass, in particular in a matrix and / or Mass based on sugars and / or sugar substitutes.
  • Sugars which may be selected from the group of sucrose, glucose, in particular dextrose, and fructose have proved particularly suitable in this connection.
  • sugar substitutes as a solid matrix or mass
  • these may in particular be selected from sugar alcohols, preferably from the group of mannitol, xylitol, sorbitol, isomalt, maltitol syrup, lactitol, leucrose, Fructooligosaccharides, glucans, polyglucose, more preferably isomalt and / or mannitol.
  • the solid dosage form contains sugar and / or sugar substitutes in a relative amount in the range of 20 to 99% by weight, in particular in the range of 30 to 90% by weight, preferably in the range of 35 to 85% by weight .-%, preferably in the range of 40 to 80 wt .-%, based on the composition contains.
  • the solid dosage form contains the at least one homeopathic active ingredient and / or component (a) in an amount in the range of 0.000001 to 1 wt .-%, in particular in the range of 0.00001 to 0.5 wt .-%, preferably in the range of 0.0001 to 0, 1 wt .-%, preferably in the range of 0.0005 to 0.01 Wt .-%, particularly preferably in the range of 0.0009 to 0.005 wt .-%, based on the composition contains.
  • the at least one homeopathic active substance for a solid dosage form may be provided, in particular, that the at least one homeopathic active ingredient and / or component (a) is an ingredient isolated and / or extracted from Arum triphyllum or that the homeopathic active ingredient and / or component (a) is at least one extract derived from Arum triphyllum or its component.
  • a solid dosage form which contains Arum triphyllum as a homeopathic active ingredient leads to an excellent alleviation of complaints associated with respiratory diseases, in particular colds.
  • acute inflammation of the upper airways and inflammation of the oral cavity and salivary glands can be treated with excellent efficacy.
  • Dehydration of the mucous membranes can also be alleviated or dehydration prevented, so that especially the symptom of hoarseness and / or oral dryness can be counteracted with high efficiency of action.
  • the solid dosage form comprises component (b) and / or the at least one mucous drug and / or the at least one mucilage in an amount in the range of 0.001 to 10% by weight, in particular in the range of 0.01 to 5 wt .-%, preferably in the range of 0.05 to 2 wt .-%, preferably in the range of 0, 1 to 1 wt .-%, particularly preferably in the range of 0.2 to 0.8 wt .-%, based on the composition contains.
  • the amount of component (b) refers to the total amount of mucilages and / or mucous drugs used in their entirety.
  • the solid dosage form contains as component (b) at least one mucilage, in particular wherein the at least one mucilage is selected from hyaluronic acid and / or their physiologically acceptable salts and / or carrageenans and / or their physiologically acceptable salts.
  • the additional use of at least one mucilage, in particular in the form of hyaluronic acid and / or carrageenans the effective efficiency of the compositions according to the invention in solid dosage form in the treatment of respiratory diseases, especially colds continue to increase.
  • the additional use of at least one mucilage, in particular hyaluronic acid and / or carrageenans leads to a further improved wetting of the upper respiratory tract mucosa, in particular of the pharynx or neck.
  • pain conditions are further alleviated by the additional use of hyaluronic acid.
  • the solid dosage form contains as component (b) a combination of hyaluronic acid and / or its physiologically compatible salts and at least one carrageenan and / or its physiologically tolerable salts.
  • the solid dosage form at least one carrageenan and / or its physiologically acceptable salts in an amount in the range of 0.0001 to 20 wt .-%, in particular in the range of 0.001 to 10 wt .-%, preferably in the range of 0.01 to 5 wt .-%, preferably in the range of 0.05 to 2 wt .-%, particularly preferably in the range of 0.1 to 1 wt .-%, based on the composition.
  • composition according to the invention is thus a composition as described above, in the form of a solid dosage form, wherein the solid dosage form in combination and in each case in effective, in particular pharmaceutically effective amounts
  • Wt .-% in particular in the range of 0.00005 to 0.5 wt .-%, preferably in the range of 0.0001 to 0.1 wt .-%, preferably in the range of 0.0005 to 0.01 wt. -%, more preferably in the range of 0.0009 to 0.005 wt .-%, based on the composition;
  • hyaluronic acid and / or physiologically acceptable salts thereof in an amount in the range of 0.00001 to 5% by weight, in particular in the range of 0.0001 to 1% by weight, preferably in the range of 0.001 to 0.5 Wt .-%, preferably in the range of 0.005 to 0.1 wt .-%, particularly preferably in the from 0.01 to 0.05 wt .-%, based on the composition, and at least one carrageenan and / or its physiologically acceptable salts in an amount in the range of 0.0001 to 20 wt .-%, in particular in the range of 0.001 to 10 wt .-%, preferably in the range of 0.01 to 5 wt .-%, preferably in the range of 0.05 to 2 wt .-%, particularly preferably in the range of 0, 1 to 1 wt .-% , based on the composition;
  • the solid dosage form is formed as a multi-phase system with at least two different phases.
  • the solid dosage form has an outer phase, in particular a capsule shell, and an inner phase, in particular a capsule core.
  • the solid dosage form as a multiphase system
  • a targeted or time-delayed release of the active ingredients or ingredients can be ensured. It may be provided in particular that after ingestion of the dosage form as a multiphase system, first the active ingredients contained in the outer phase, in particular the capsule shell, are released. Later, or delayed, the release of the active ingredients or ingredients, which are in the inner phase, in particular capsule core, then takes place.
  • the release of the active ingredients can be adjusted in a targeted manner or the release can be controlled in such a way that the active ingredients complement each other optimally in relation to their profile of action or unfold their effect successively and in addition to one another.
  • the solid dosage form in the form of a multiphase system has a capsule shell on the one hand and a capsule core on the other hand, ie the solid dosage form is based on a core / shell principle "is constructed so that not all phases after application of the capsule system for body fluids, especially saliva and / or gastric acid, free are accessible and a sustained release in particular of the active ingredients contained in the capsule core is made possible.
  • the solid dosage form contains the outer phase, in particular the capsule shell, in an amount in the range from 30 to 99% by weight, in particular in the range of 40 to 98 wt .-%, preferably in the range of 50 to 96 wt .-%, preferably in the range of 60 to 95 wt .-%, particularly preferably in the range of 70 to 92 wt .-%, still more preferably in the range of 80 to 90% by weight, based on the composition.
  • the solid dosage form the inner phase, in particular the capsule core, in an amount in the range of 1 to 70 wt .-%, in particular in the range of 2 to 50 wt .-%, preferably in the range From 3 to 40% by weight, preferably in the range from 5 to 30% by weight, more preferably in the range from 7 to 20% by weight, even more preferably in the range from 8 to 15% by weight, based on the Composition comprising.
  • the solid dosage form contains the homeopathic active ingredient and / or the component (a) in the outer phase and / or in the inner phase, in particular in the inner phase, preferably in the Capsule core, contains.
  • the solid dosage form contains the at least one homeopathic active ingredient and / or component (a) in an amount in the range of 0 , 0001 to 5% by weight, in particular in the range of 0.001 to 3 wt .-%, preferably in the range of 0.01 to 1 wt .-%, preferably in the range of 0.1 to 0.5 wt .-%, based on the composition contains.
  • the solid dosage form contains the at least one homeopathic active ingredient and / or the component (a) - as mentioned above - preferably in the inner phase, in particular the capsule core.
  • component (a) or of the homeopathic active substance it is preferred according to the invention if this or these is at least one ingredient isolated from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica , Likewise, it may be provided in this context that the homeopathic active ingredient and / or component (a) is at least one extract or component thereof derived from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica.
  • a homeopathic active ingredient based on sundew or species of the genus Drosera in particular in multiphase systems with sustained release, has an excellent profile of action in the treatment of respiratory diseases, in particular the symptoms of colds.
  • the homeopathic active ingredient leads to a relief of coughing and hoarseness.
  • the pain symptoms associated with cold sores are alleviated.
  • the solid dosage form component (b) in the outer phase and / or in the inner phase preferably in the outer phase, in particular the capsule shell, and in the inner phase, in particular the capsule core contains.
  • the solid dosage form contains component (b) and / or the at least one mucous drug and / or the at least one mucilage in an amount in the range from 0.001 to 20% by weight, in particular in the range from 0.01 to 15 wt .-%, preferably in the range of 0, 1 to 10 wt .-%, preferably in the range of 0.5 to 5 wt .-%, particularly preferably in the range of 1 to 2 wt .-%, based on the Composition containing.
  • the solid dosage form comprises component (b) and / or the at least one mucous drug and / or the at least one mucilage in the outer phase, in particular the capsule shell, in an amount in the range from 0.001 to 10% by weight, in particular in the range from 0.01 to 5% by weight, preferably in the range from 0.05 to 2.5% by weight, preferably in the range from 0.1 to 1, 5 wt .-%, based on the composition contains.
  • the solid dosage form contains component (b) and / or the at least one mucous drug and / or the at least one mucilage in the inner phase, in particular the capsule core, in an amount in the range from 0.0001 to 1 Wt .-%, in particular in the range of 0.001 to 0.5 wt .-%, preferably in the range of 0.005 to 0.1 wt .-%, preferably in the range of 0.01 to 0.09 wt .-% , based on the composition contains.
  • component (b) in the abovementioned amounts both in the capsule shell and in the capsule core, an outstanding efficiency of action of the composition according to the invention in the treatment of respiratory diseases, in particular colds, is achieved.
  • the delayed release released homeopathic active ingredient in particular based on Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, reinforced in its effect.
  • the solid dosage form in the outer phase, in particular the capsule shell, as component (b) contains a combination of at least one mucous drug and at least one mucilage, in particular wherein the mucus drug Marshmallow (Althaea officinalis L.) and the mucilage is at least one carrageenan and / or its physiologically acceptable salts.
  • the solid dosage form in the inner phase in particular the capsule core, as component (b) contains at least one mucilage, in particular wherein the mucilage is at least one carrageenan and / or its physiologically acceptable salts.
  • component (b) contains at least one mucilage, in particular wherein the mucilage is at least one carrageenan and / or its physiologically acceptable salts.
  • a protective film forms on the mucous membrane, which on the one hand leads to wetting or rehydration of the irritated mucous membranes and moreover has a barrier effect against other pathogens, such as bacteria or viruses.
  • the amounts of the selected slime drugs or mucilages used can vary within wide ranges.
  • the solid dosage form in the outer phase, in particular the capsule shell as component (b) at least one mucilage, in particular at least one carrageenan and / or its physiologically acceptable salts, in an amount in the range from 0.0001 to 2% by weight, in particular in the range of 0.001 to 1, 5 wt .-%, preferably in the range of 0.01 to 1 wt .-%, preferably in the range of 0.1 to 0.5 Wt .-%, based on the composition contains.
  • the outer phase in particular the capsule shell, and / or the inner phase, in particular the capsule core, at least one Sugar and / or sugar substitute. It has proved to be advantageous if the at least one sugar is selected from the group of sucrose, glucose, in particular dextrose, and fructose.
  • the at least one sugar substitute is selected from the group of sugar alcohols, preferably from the group of mannitol, xylitol, sorbitol, isomalt, maltitol syrup, lactitol, leucrose, fructo-oligosaccharides, glucans, polyglucose, particularly preferably isomalt and / or maltitol.
  • sugar alcohols preferably from the group of sugar alcohols, preferably from the group of mannitol, xylitol, sorbitol, isomalt, maltitol syrup, lactitol, leucrose, fructo-oligosaccharides, glucans, polyglucose, particularly preferably isomalt and / or maltitol.
  • both the outer phase and the inner phase have sugars or sugar substitutes.
  • the solid dosage form in the outer phase in particular the capsule shell, at least one sugar and / or sugar substitute, in particular isomalt, in an amount in the range of 50 to 99 wt .-%, in particular in the range from 60 to 97% by weight, preferably in the range from 70 to 95% by weight, preferably in the range from 80 to 90% by weight, based on the composition.
  • the composition in the inner phase in particular the capsule core, at least one sugar and / or sugar substitute, in particular maltitol, in an amount in the range of 1 to 50 wt .-%, in particular in the range of 2 to 25 wt .-%, preferably in the range of 5 to 20 wt .-%, preferably in the range of 7 to 10 wt .-%, based on the composition contains.
  • the present invention - is thus a solid dosage form based on a multiphase system, wherein the solid dosage form in combination and in each case in effective, in particular pharmaceutically effective amounts
  • At least one carrageenan and / or its physiologically acceptable salts in an amount in the range of 0.0001 to 2 wt .-%, in particular in the range of 0.001 to 1, 5 wt .-%, preferably in the range of 0.01 to 1 Wt .-%, preferably in the range of 0.1 to 0.5 wt .-%, based on the composition; and
  • Marshmallow (Althaea officinalis L.), in an amount in the range of 0.001 to 8% by weight, in particular in the range of 0.01 to 4% by weight, preferably in the range of 0.05 to 2% by weight, preferably in the range of 0.1 to 1.3% by weight, based on the composition;
  • At least one carrageenan and / or its physiologically acceptable salts in an amount in the range of 0.0001 to 1 wt .-%, in particular in the range of 0.001 to 0.5 wt .-%, preferably in the range of 0.005 to 0.1 wt .-%, preferably in the range of 0.01 to 0.09 wt .-%, based on the composition,
  • the composition is present as a liquid dosage form and / or that the composition is in the form of a fluid, mouthwash, mouthwash, juice, gargle solution or the like, in particular as a juice, is present.
  • the liquid administration form is a cervical and / or cough syrup.
  • the liquid dosage form contains the homeopathic active ingredient and / or component (a) in an amount in the range from 0.01 to 20% by weight, in particular in the range from 0, From 05 to 15% by weight, preferably in the range from 0.1 to 10% by weight, preferably in the range from 0.5 to 5% by weight, particularly preferably in the range from 0.7 to 2% by weight , based on the composition contains.
  • component (a) or of the homeopathic active substance it has also surprisingly been found that a particularly good effectiveness is achieved if the homeopathic active ingredient and / or component (a) at least one from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, isolated and / or extracted ingredient is or if the homeopathic active ingredient and / or component (a) at least one from Drosera, especially Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, extracted extract or its component.
  • Drosera in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica
  • isolated and / or extracted ingredient is or if the homeopathic active ingredient and / or component (a) at least one from Drosera, especially Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, extracted extract or its component.
  • the homeopathic active ingredient from Drosera in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, in liquid compositions, in particular in combination with at least one mucilaginous or at least one mucilage, to an excellent efficacy in the context of the treatment of respiratory diseases, especially symptoms of colds.
  • the coughing stimulus can be alleviated on this basis. Also, sore throat and hoarseness can be successfully treated.
  • the liquid dosage form component (b) and / or the at least a mucous drug and / or the at least one mucilage in an amount in the range from 0.1 to 30% by weight, in particular in the range from 0.5 to 20% by weight, preferably in the range from 1 to 15% by weight , preferably in the range of 5 to 13 wt .-%, based on the composition contains.
  • the liquid dosage form contains as component (b) at least one mucous drug, preferably a combination of two mucous drugs, in particular wherein the mucous drugs selected may be from Icelandic moss (Althaea officinalis L.) and / or mallow (Malva sylvestris L. and M. neglecta WALLR.).
  • the liquid dosage form as component (b) contains Icelandic moss (Althaea officinalis L.) in an amount in the range from 0.01 to 20% by weight, in particular in the range from 0.1 to 15% by weight, preferably in the range from 1 to 10% by weight, preferably in the range from 3 to 7% by weight, based on the composition.
  • Icelandic moss Althaea officinalis L.
  • the liquid dosage form as component (b) mallow (Malva sylvestris L. and M. neglecta WALLR.) In an amount in the range of 0.01 to 20 wt .-%, in particular in the range of 0, 1 to 15 wt .-%, preferably in the range of 1 to 10% by weight, preferably in the range of 3 to 7 wt .-%, based on the composition contains.
  • the composition according to the invention in the form of a liquid administration form as component (b) contains Icelandic moss and mallow in combination.
  • the liquid dosage form contains at least one trace element and / or its physiologically acceptable salts.
  • the at least one trace element and / or its physiologically acceptable salts from the group of chromium (Cr), cobalt (Co), iron (Fe), fluorine (F), iodine (I), copper (Cu), manganese (Mn), molybdenum (Mo), selenium (Se), silicon (Si) and / or zinc (Zn), preferably zinc , more preferably in the form of zinc gluconate.
  • the amount of the at least one trace element used is concerned, this is variable.
  • the liquid dosage form comprises the at least one trace element in an amount in the range of 0.00001 to 10 wt .-%, in particular in the range of 0.0001 to 1 wt .-%, preferably in the range of 0.001 to 0.5 wt .-%, preferably in the range of 0.01 to 0.1 wt .-%, based on the composition contains.
  • the liquid dosage form is aqueous, alcoholic or aqueous alcoholic based.
  • the liquid dosage form contains the active ingredients and / or ingredients together with a harmless, in particular pharmacologically and / or physiologically acceptable carrier and / or excipient.
  • the carrier in particular, it may be provided that it is selected from the group of solvents, solubilizers, emulsifiers and the like or that the carrier is selected from the group of water, ethanol, isopropanol, ethyl carbonate, ethyl acetate , Benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylglycol and combinations thereof.
  • the liquid dosage form has at least one sugar and / or sugar substitute.
  • the sugar may be selected from the group of sucrose, glucose, especially dextrose, and fructose.
  • the at least one sugar substitute is selected from sugar alcohols, preferably from the group of mannitol, xylitol, sorbitol, isomalt, maltitol syrup, lactitol, leucrose, fructo-oligosaccharides, glucans, polyglucose, particularly preferably maltitol syrup.
  • the liquid dosage form contains water, in particular in an amount of at least 10 wt .-%, in particular at least 20 wt .-%, preferably at least 30 wt .-%, based on the composition, and / or in particular in an amount in the range from 10 to 98% by weight, in particular in the range from 20 to 95% by weight, preferably from 30 to 90% by weight, based on the composition.
  • a liquid dosage form based on at least one homeopathic active ingredient, in particular Drosera, preferably Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, on the one hand and at least one mucous drug, in particular Icelandic moss and mallow, on the other hand has an excellent efficacy in connection with the treatment of respiratory diseases, especially colds or influenza infections.
  • the composition according to the invention in liquid dosage form leads to an excellent alleviation of the symptoms associated with cold sores, such as sore throat, hoarseness, cough and mucosal irritation.
  • the present invention is therefore in particular a composition, as described above, in the form of a liquid dosage form, wherein the liquid dosage form in combination and in each case in effective, in particular pharmaceutically effective amounts
  • Mallow Mallow (Malva sylvestris L. and M. neglecta WALLR.) In an amount in the range of 0.01 to 20% by weight, in particular in the range of 0.1 to 15% by weight. %, preferably in the range of 1 to 10 wt .-%, preferably in the range of 3 to 7 wt .-%, based on the composition;
  • composition is present as a spray and / or aerosol, in particular as a spray, preferably for nasal administration.
  • the spray and / or aerosol in an amount in the range of 0.001 to 5 wt .-%, in particular in the range of 0.005 to 3% by weight, preferably in the range of 0.01 to 1 wt .-%, preferably in the range of 0, 1 to 0.5 wt .-%, based on the composition , contains.
  • component (a) particularly good results are achieved with regard to the effectiveness of the compositions when the at least one homeopathic active ingredient and / or component (a) contains at least one ingredient isolated and / or extracted from Galphimia glauca or if the homeopathic active ingredient and / or component (a) is at least one extract or its component derived from Galphimia glauca.
  • the efficiency of action of a composition based on a spray or aerosol according to the invention can be increased even further if the spray and / or aerosol contains component (b) and / or the at least one mucous drug and / or the at least one mucilage in an amount in the range of 0.00001 to 1, 5 wt .-%, in particular in the range of 0.0001 to 1 wt .-%, preferably in the range of 0.001 to 0.8 wt .-%, preferably in the range of 0.1 to 0.5 wt .-%, based on the composition contains.
  • the spray and / or aerosol contains at least one mucilage as component (b).
  • the at least one mucilage is hyaluronic acid or its physiologically tolerable salts.
  • the symptoms associated with respiratory allergic diseases such as runny nose, nasal congestion, coughing and sneezing attacks, and itching and watery eyes, can be alleviated with high efficiency.
  • the effectiveness or effectiveness of the composition according to the invention can be further increased if the spray and / or aerosol as further component (c) pantothenol, preferably dexpanthenol (D-pantothenol), or its physiologically acceptable esters and / or pantothenic acid or its physiological compatible salts.
  • the irritated and sometimes damaged nasal mucosa can be treated and cured or regenerated on the basis of the wound-healing-promoting properties of panthotenol or dexpanthenol and / or pantothenic acid.
  • the spray and / or aerosol component (c) in an amount in the range of 0.01 to 20 wt .-%, in particular in the range from 0, 1 to 10 wt .-%, preferably in the range of 0.5 to 5 wt .-%, preferably in the range of 1 to 3 wt .-%, based on the composition.
  • the spray and / or aerosol contains as further component (d) at least one physiologically acceptable, osmotically active substance or at least one physiologically acceptable osmolyte.
  • the osmotically active substances and / or the osmolytes may in particular be selected from the group of ions of physiologically acceptable salts (ie salt ions), in particular alkali ions, in particular sodium ions and / or potassium ions, and / or chloride ions, preferably sodium ions and chloride ions; Sugars, in particular trehalose and / or sucrose; Polyols, in particular glycerol; and / or amino acids, in particular glutamic acid and / or its physiologically tolerated salts, proline, (hydroxy) ectoine and / or glycine betaine.
  • physiologically acceptable salts ie salt ions
  • alkali ions in particular sodium ions and / or potassium ions
  • chloride ions preferably sodium ions and chloride ions
  • Sugars in particular trehalose and / or sucrose
  • Polyols in particular glycerol
  • amino acids in particular glutamic acid and / or its physiologically
  • the osmotically active substances and / or the osmolytes are sodium ions and chloride ions, in particular in the form of sodium chloride.
  • Under osmotically active substances or osmolytes are usually understood substances that can affect the osmotic state of a system, in particular of cells.
  • the composition can be provided on the basis of a hyperosmolar or hypoosmolar or isotonic solution.
  • a certain astringent effect of the composition according to the invention or decongestant effects can be achieved without the use of a downsweller, such as an alpha-sympathomimeticum, necessary .
  • the increased content of osmotically active substances or osmolytes compared to the cells of the nasal mucosa removes excessively bound water from the cells of the nasal mucosa, so that the nasal mucous membrane swells and nasal breathing is improved.
  • the spray and / or aerosol contains component (d) in an amount in the range from 0.001 to 10% by weight, in particular Range of 0.01 to 5 wt .-%, preferably in the range of 0.1 to 3 wt .-%, preferably in the range of 1 to 2 wt .-%, based on the composition contains.
  • the spray and / or aerosol contains at least one acid and / or base, in particular for forming a buffer system.
  • the composition contains at least one buffer system or that the composition preferably contains at least one base.
  • the spray and / or aerosol contains water. It has proved to be particularly advantageous if the spray or aerosol in an amount in the range of 80 to 99 wt .-%, preferably in the range of 85 to 98 wt .-%, preferably in the range of 90 to 97 Wt .-%, particularly preferably in the range of 93 to 96 wt .-%, based on the composition.
  • the present invention according to a further preferred embodiment according to the invention is thus a composition in the form of a spray or aerosol, wherein the spray and / or aerosol in combination and in each case in effective, in particular pharmaceutically effective amounts
  • 1, 5 wt .-% in particular in the range of 0.0001 to 1 wt .-%, preferably in the range of 0.001 to 0.8 wt .-%, preferably in the range of 0.1 to 0.5 wt. %, based on the composition;
  • pantothenol optionally pantothenol, preferably dexpanthenol (D-pantothenol), or its physiologically acceptable ester and / or pantothenic acid or its physiologically acceptable salts, in an amount in the range of 0.01 to 20 wt .-%, in particular in the range of 0 , 1 to 10 wt. preferably in the range of 0.5 to 5 wt .-%, preferably in the range of 1 to 3 wt .-%, based on the composition; and
  • compositions in the form of a spray and / or aerosol, in particular for nasal administration which is distinguished by an outstanding efficiency of action with regard to the treatment of allergic respiratory diseases, but at least substantially none thereof Side effects, such as those associated with antihistamines or corticosteroids in particular.
  • excellent anti-allergic efficacy is achieved even without the additional use of corticosteroids and / or antihistamines.
  • the present invention thus also provides a composition as described above for use in the prophylactic and / or therapeutic treatment of respiratory diseases, in particular colds and / or allergies, in particular influenza infections, runny nose, cough, cold-related or allergic rhinitis, hoarseness and / or sore throat. Furthermore, the present invention relates - according to another aspect - the use of a composition, as described above, in the prophylactic and / or therapeutic treatment of respiratory diseases, especially colds and / or allergies, especially influenza infections, runny nose, cough, cold-related or allergic rhinitis, hoarseness and / or sore throat.
  • dosage forms of the present invention are provided in the form of lozenges, multi-phase lotion tablets, cough syrup and nasal spray and tested on subjects for efficacy.
  • lozenges according to the invention with the active ingredient combination Arum triphyllum, carrageenans and hyaluronic acid are provided with the tabletting method known to the person skilled in the art.
  • the homeopathic active ingredients based on Arum triphyllum are used in a dilution or potency of D6 compared to the mother tincture, wherein the mother tincture according to the usual rules, as described in the homeopathic pharmacopoeia, is produced.
  • the preparation of the lozenges is carried out in a manner known to those skilled in the art, d. H. with respect to the merging of the ingredients and the subsequent tabletting no further comments are necessary at this point.
  • the tablets prepared in this way are tested to test their efficacy on 20 people aged 15 to 60 years suffering from influenza-type infections and associated symptoms, especially coughing and hoarseness.
  • the subjects receive a lozenge four times a day, which is slowly sucked in the mouth.
  • the treatment duration is five days.
  • a significant improvement or relief of cold symptoms can be found.
  • sore throat, irritable cough, hoarseness and inflammatory symptoms can be alleviated. Side effects are not observed in the subjects.
  • compositions according to the invention in the form of lozenges with Arum triphyllum, carrageenans and hyaluronic acid as active ingredients are distinguished by their outstanding efficacy in the treatment of symptoms associated with influenza-like infections.
  • compositions according to the invention are provided in the form of two-phase lozenges with a combination of active substances based on marshmallow root, carrageenans and Drosera.
  • the lozenges are provided by methods well known to those skilled in the art.
  • the two-phase lozenges according to the invention are provided by means of methods generally known to those skilled in the art for providing core / sheath capsules.
  • the mother tincture of the homeopathic drug based on Drosera is provided in accordance with the usual provisions of the European Pharmacopoeia and adjusted to a dilution or potency of D6.
  • the marshmallow root extract used has a drug / extract ratio of about 1: 1.
  • 20 persons aged 15 to 60 who suffer from influenza-type infections and the associated symptoms, in particular dry, dry coughing and hoarseness are consulted.
  • the subjects receive a lozenge four times a day, which is slowly sucked in the mouth.
  • the treatment duration is five days.
  • the symptoms of cold, especially the cough and hoarseness have improved significantly in all persons.
  • the onset of action of the lozenges according to the invention is also extremely fast, i. already with the sucking of the first tablet, the subjects report an improvement of the acute symptoms, especially hoarseness.
  • the composition is characterized by its excellent compatibility; No adverse reactions are documented for any subject.
  • composition based on two-phase lozenges according to the invention are outstandingly suitable for the treatment of respiratory diseases, in particular influenza-like infections, or the associated symptoms.
  • respiratory diseases in particular influenza-like infections, or the associated symptoms.
  • the combination of the carbohydrate-based mucilage and the mucous drug based on marshmallow root forms a protective layer on the mucous membrane, so that the mucous membrane can regenerate and, moreover, is shielded against further irritation.
  • the used homeopathic drug Drosera has an anti-inflammatory effect.
  • compositions according to the invention are provided in the form of a juice with a combination of active ingredients based on Icelandic moss, mallow and Drosera.
  • the juice is provided by methods known to those skilled in the art.
  • the cress juice is provided on the basis of manufacturing processes known per se to those skilled in the art.
  • the plant extracts used ie Icelandic moss and mallow, have a drug / extract ratio of 1: 1.
  • the homeopathic drug on Bas / 's of Drosera in potency D6 against the mother tincture is present.
  • the juice of the present invention is distinguished by its excellent efficacy in the treatment of cold symptoms, especially sore throat, irritable cough and hoarseness.
  • compositions according to the invention are provided in the form of a nasal spray with a combination of active substances based on hyaluronic acid, dexpanthenol and Galphimia glauca.
  • the nasal spray is provided by methods generally known to those skilled in the art.
  • the used mother tincture of Galphimia glauca is obtained according to the usual regulations of the homeopathic pharmacopoeia and adjusted to a potency or dilution of D6 compared to the mother tincture.
  • the symptoms associated with allergic rhinitis are significantly alleviated.
  • a swelling of the nasal mucosa can be achieved, so that the free nasal breathing is possible again.
  • the nasal spray according to the invention has a positive effect on the wound healing of the inflamed and irritated nasal mucosa.
  • the nasal spray according to the invention makes it possible to treat allergy-related symptoms without side effects and with high efficiency.

Abstract

La présente invention concerne une composition, en particulier une composition pharmaceutique, à utiliser de préférence dans le traitement prophylactique et/ou thérapeutique de maladies respiratoires, notamment les refroidissements et/ou les allergies, qui contient d'une part au moins un principe actif homéopathique efficace contre les refroidissements et/ou les allergies, et d'autre part au moins un agent mucolytique et/ou au moins une substance mucilagineuse.
EP16751231.8A 2015-11-25 2016-07-29 Composition pour le traitement de refroidissements et d'allergies Withdrawn EP3380109A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102015015145 2015-11-25
DE102015121607.8A DE102015121607A1 (de) 2015-11-25 2015-12-11 Zusammensetzung zur Behandlung von Erkältungskrankheiten und Allergien
PCT/EP2016/068143 WO2017088992A1 (fr) 2015-11-25 2016-07-29 Composition pour le traitement de refroidissements et d'allergies

Publications (1)

Publication Number Publication Date
EP3380109A1 true EP3380109A1 (fr) 2018-10-03

Family

ID=57582565

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16751231.8A Withdrawn EP3380109A1 (fr) 2015-11-25 2016-07-29 Composition pour le traitement de refroidissements et d'allergies

Country Status (3)

Country Link
EP (1) EP3380109A1 (fr)
DE (2) DE102015121607A1 (fr)
WO (1) WO2017088992A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019120555A1 (de) * 2019-07-30 2021-02-04 Gerald Kaupp Pflanzliche Zusammensetzung für die orale Erkältungsmedikation und Verfahren zu ihrer Herstellung
DE102020007979A1 (de) 2020-12-29 2022-06-30 Charité Universitätsmedizin Institut für Mikrobiologie und Infektionsimmunologie Zusammensetzung zur Behandlung von lnfektionen mit Coronaviren

Also Published As

Publication number Publication date
WO2017088992A1 (fr) 2017-06-01
DE102015121607A1 (de) 2017-06-01
DE202015106754U1 (de) 2016-11-28

Similar Documents

Publication Publication Date Title
EP2874600B1 (fr) Composition pharmaceutique pour le traitement d'enrouement et de mal à la gorge
EP2293805B1 (fr) Composition à sucer pour le traitement d'affections inflammatoires de la cavité buccale et du pharynx
EP1829548A1 (fr) Utilisation d'extraits de Pelargonium sidoides en association avec d'extraits de Plantago lanceolata pour la préparation d'un médicament pour le traitement de la pharyngite
EP2367557B1 (fr) Composition pour le traitement de maladies infectieuses de la cavité buccale et pharyngienne
DE102009005865A1 (de) Dosiereinheit und Zusammensetzung zur Behandlung von entzündlichen Erkrankungen des Mund- und Rachenraums
DE202006011920U1 (de) Zusammensetzung zur Behandlung von Rhinitis
EP1639998B1 (fr) Losange à base de mucilage de plantes contre les processus inflammatoires de la cavité buccale et pharyngienne
EP1871340B1 (fr) Medicament antitussif et sedatif contenant des extraits de mousse d'islande et de mauve et en plus des derives de zinc
EP3380109A1 (fr) Composition pour le traitement de refroidissements et d'allergies
EP2617412B1 (fr) Composition pour le traitement topique
EP3285791A1 (fr) Composition pour le traitement de la cavité laryngopharyngée
EP2874601B1 (fr) Composition, en particulier composition pharmaceutique, destinée notamment à être administrée en cas d'enrouement
EP3285790A1 (fr) Composition pour le traitement de la cavité laryngopharyngée
DE202006008541U1 (de) Reizlinderndes Hustenmittel
EP3129031B1 (fr) Composition utilisée pour le traitement des troubles gastriques
DE202015104316U1 (de) Zusammensetzung für die Behandlung des Hals-/Rachenraums
DE202004016078U1 (de) Schleimdrogenbasierte Lutschtablette gegen entzündliche Erkrankungen des Mund- und Rachenraums
DE202005009181U1 (de) Reizlinderndes Hustenmittel
DE202005018338U1 (de) Lutschtablette gegen Hustenreiz und Heiserkeit

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190426